Neurology

Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS

Retrieved on: 
Sunday, May 5, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Neurology, Mental Health, Health Technology, Medical Devices, Software, FDA, Brain, International Society, Diffusion, GE HealthCare, Hospital, Neuroscience, Doctor of Philosophy, Research, TES, Environment, Mathematics, Microcirculation, Patient, Magnetic resonance, DSM-IV codes, MRI, Diagnosis, Biomarker, Annual general meeting, Medical imaging

SIGNA MAGNUS represents GE HealthCare’s vision of our most advanced 3.0T MR imaging device, specifically designed for the highest standards of neurological and oncological research for head-only imaging.

Key Points: 
  • SIGNA MAGNUS represents GE HealthCare’s vision of our most advanced 3.0T MR imaging device, specifically designed for the highest standards of neurological and oncological research for head-only imaging.
  • Through SIGNA MAGNUS, GE HealthCare will help to empower neuroscientists, neurologists, neuroradiologists and oncologists to transcend barriers, with the goal of enhancing the diagnosis, understanding, and treatment of complex diseases.
  • Researchers can fully utilize SIGNA MAGNUS capabilities to push the boundaries of advanced anatomical, diffusion and functional techniques, amplified by the latest deep-learning algorithms that GE HealthCare has to offer.
  • Additionally, many GE HealthCare 3.0T systems are upgradable to SIGNA MAGNUS, which will help potential customers to save on capital costs.

MiRNA Sequencing and Assay Market Research 2024: Robust Growth with Emerging Trends in Personalized Medicine and Advancements in Sequencing Technologies - Global Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 3, 2024
Biotechnology, Genetics, Health, Cancer, Genomics, Prognosis, Cardiology, RNA, Traction, Research, NGS, Disease, Patient, Neurology, Data analysis, Gene expression, Diagnosis, Messenger, Biomarker, Molecular biology, Immunity, Risk assessment, Drug discovery, Medicine, Algorithm, Medical imaging

One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.

Key Points: 
  • One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.
  • This has led to a surge in the adoption of miRNA sequencing and assay technologies in both research and clinical settings.
  • The integration of bioinformatics tools has emerged as a significant driver in boosting the Global MiRNA Sequencing and Assay Market.
  • The rising interest in personalized medicine has emerged as a powerful catalyst in boosting the Global MiRNA Sequencing and Assay Market.

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

Retrieved on: 
Friday, May 3, 2024
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Neuromuscular disease, SRPT, National academy, DSM-IV codes, Hospital, Muscular dystrophy, Book, SMA, Cell, Duchenne, Disease, TIME, Patient, Sarepta Therapeutics, Gene, Society, Nationwide, Duchenne muscular dystrophy, Head, Therapy, Global health, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.
  • The TIME100 Health list recognizes the impact, innovation, and achievement of the world’s most influential individuals in health.
  • In addition to recognition on the TIME100 Health list, Dr. Mendell is a 2024 recipient of the King Faisal Prize Laureate in Medicine.
  • He is also a published author of more than 400 peer-reviewed articles and books about skeletal muscle disease, peripheral nerve disorders and gene therapy.

Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 2, 2024
Research, General Health, Professional Services, Pharmaceutical, Infectious Diseases, Clinical Trials, Science, Biotechnology, Neurology, FDA, Finance, Health, Other Science, L.L.C, Longboard, Farallon Capital, Investment, Private, Food, FINANCIAL, Insurance, SAD, AAN, DSM-IV codes, Clinical trial, Medication, Food and Drug Administration

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.
  • In January 2024, Longboard raised $241.5 million in a follow-on public offering.
  • Longboard issued and sold 11,500,000 shares of common stock at a public offering price of $21.00 per share.
  • In March 2024, Longboard completed a Private Placement with an investment fund affiliated with Farallon Capital Management, L.L.C.

4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration

Retrieved on: 
Thursday, May 2, 2024
Mental Health, Health, Neurology, Research, Science, Pharmaceutical, Biotechnology

This group of experts join Dr. Maurizio Fava, the company’s clinical consultant, in providing invaluable guidance and insights to the 4M Therapeutics management team.

Key Points: 
  • This group of experts join Dr. Maurizio Fava, the company’s clinical consultant, in providing invaluable guidance and insights to the 4M Therapeutics management team.
  • “Our newly formed Clinical Advisory Board brings together pioneers from top institutions across the country dedicated to treating central nervous system disorders,” said Dr. Pablo Lapuerta, Chief Executive Officer and Co-Founder of 4M Therapeutics.
  • He is board certified in Internal Medicine by the American Board of Internal Medicine and in Psychiatry by the American Board of Psychiatry and Neurology.
  • He is also a Certified Physician Investigator (CPI) from the Association of Clinical Research Professionals (ACRP).

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Retrieved on: 
Thursday, May 2, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, Therapy, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.
  • The company will hold a conference call at 4:30 p.m. Eastern on Thursday, May 9, which will be open to the public.
  • During the conference call, the company will review its financial results and provide business updates.
  • The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events .

ONO PHARMA USA Announces 2024 Golden Ticket Competition Now Accepting Applications from Innovative Startups

Retrieved on: 
Thursday, May 2, 2024
Immunology, Golden Ticket, ONO, Patient, Neurology, MBC, Kendall Square, The Golden Ticket, LabCentral, Organization

CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company. The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.

Key Points: 
  • CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company.
  • The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.
  • The Golden Ticket awards provide two promising early-stage R&D companies lab space and mentorship, components that are vital to the success of promising life science businesses.
  • The competition seeks proposals from startup companies in the oncology, immunology, neurology, and specialty areas.

Emergency Departments Frequently Miss Signs of Epilepsy in Children

Retrieved on: 
Wednesday, May 1, 2024
Roger Hawkins (drummer), University, Stroke, Seizure, Hospital, Risk, Death, DSM-IV codes, NYU Langone Health, Partnership, Doctor of Philosophy, Research, Emotion, NYU, History, Knowledge, Patient, Physician, Neurology, Epilepsy, Child, Diagnosis, Einstein Medical Center Philadelphia, Brain, Panic, Amnesia, Anxiety, Pharmaceutical industry

The work focuses on "nonmotor" seizures, which cause children to "zone out" and stare into space or fidget.

Key Points: 
  • The work focuses on "nonmotor" seizures, which cause children to "zone out" and stare into space or fidget.
  • To be diagnosed with the condition, a patient must have experienced a minimum of two seizures with no apparent cause.
  • Their analysis showed that emergency department physicians correctly identified only 33% of first-time nonmotor seizures, compared with 81% of first-time motor seizures.
  • According to the United States Centers for Disease Control and Prevention, epilepsy is one of the most common brain disorders in children, affecting 470,000 under age 17.

Myasthenia Gravis Foundation of America (MGFA) Kicks off Annual National MG Patient Conference With Program Announcements

Retrieved on: 
Monday, April 29, 2024
Online, Education, FDA, Patient, Language, Learning, Social work, Muscle weakness, Myasthenia gravis, Conference, Convention center, Myasthenia, Research, Human, Neurology, Disease, Registry, Fatigue, Caregiver, Community, Quality of life, MGFA, Nursing

TAMPA BAY, Fla., April 29, 2024 /PRNewswire/ -- More than 400 members of the myasthenia gravis (MG) rare disease community will come together this week at the MGFA National Patient Conference for support and a better understanding of how to manage their disease while learning about the latest in treatments and clinical studies.  

Key Points: 
  • Myasthenia Gravis Foundation of America (MGFA™) , the largest, leading patient advocacy organization solely dedicated to the myasthenia gravis community kicked off its annual conference today with a volunteer awards dinner and new program announcements.
  • The conference features patient stories and individuals diagnosed with myasthenia gravis as well as presentations and discussions from patients, caregivers, researchers, MG expert clinicians, and pharmaceutical and industry partners.
  • Bringing together MG patients and other members of the community to learn from and support each other is so powerful," said Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America.
  • MGFA Global MG patient Registry – The MGFA Global MG Patient Registry gives the MG community a loud voice in ensuring that research studies and clinical trials are built to evaluate the most promising MG research.

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Retrieved on: 
Friday, May 3, 2024
University, Part, CMO, Federal republic, Research, Cancer, Federal Patent Court (Germany), Vaccine, Business, Webcast, BioNTech, District court, Whole genome sequencing, Vaccination, Public, WHO, Hearing loss, Cardiology, Animal, EP 1, Omicron, GSK, Systems biology, Workforce, Infection, Messenger, Federal court, Therapy, Data monitoring committee, Safety, Monroe Dunaway Anderson, CVAC, Justice, RNA, Astrocytoma, Motion, Human, CureVac, Pandemic, GMP, Sąd rejonowy, SARS-CoV-2, Business development, Epitope, MD, Acuitas Therapeutics, DSMB, Ageing, Patent, Patient, Neurology, Operating cost, H5N1, MD Anderson Cancer Center, PPA, Interim, MBA, Antigen, COVID-19, Amgen

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2023 and provided a business update.
  • “We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose.
  • Thaminda Ramanayake was appointed to the CureVac Management Team as Chief Business Officer effective June 1, 2024.
  • Mr. Ramanayake joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.